PTH COMPOUNDS WITH LOW PEAK-TO-MINIMUM RATIOS Russian patent published in 2022 - IPC A61K38/29 A61K47/60 A61P5/18 

FIELD: medicine; pharmaceutics.

SUBSTANCE: invention relates to the field of medicine and pharmaceutics, namely to the use of a pharmaceutical composition containing a parathyroid hormone (hereinafter – PTH) compound for the treatment of hypoparathyroidism, where the PTH compound is a water-soluble PTH compound of controlled release of the formula (IIf-i)

(IIf-i),

where an unmarked dotted line is the attachment to a nitrogen atom of a PTH component by means of an amide connection; and a dotted line marked with the asterisk is the attachment to a component

,

where m and p are independently an integer in the range of 400-500, inclusively; where the PTH component has a sequence selected from SEQ ID NO:47-SEQ ID NO:55 or SEQ ID NO:107-SEQ ID NO:115; where after subcutaneous injection to a primate other than human, a pharmacokinetic profile of the PTH compound shows a peak-to-minimum ratio in plasma of less than 4 during one interval of the injection in a stationary state, where a period of time between two subsequent subcutaneous injections is 24 hours.

EFFECT: invention provides for periodical PTH injection with lower increase in bone remodeling markers due to decreased peak-to-minimum ratio of concentration after subcutaneous injection, which reduces side effects of the therapy.

12 cl, 29 ex